Aurora Investment Counsel Sells 118 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Aurora Investment Counsel lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,437 shares of the company’s stock after selling 118 shares during the period. Aurora Investment Counsel’s holdings in Neurocrine Biosciences were worth $1,437,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of NBIX. The Manufacturers Life Insurance Company raised its position in Neurocrine Biosciences by 18.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 116,955 shares of the company’s stock valued at $15,410,000 after purchasing an additional 18,070 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Neurocrine Biosciences by 3.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 252,565 shares of the company’s stock valued at $34,834,000 after acquiring an additional 8,630 shares in the last quarter. Vanguard Group Inc. increased its position in Neurocrine Biosciences by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock valued at $1,279,433,000 after purchasing an additional 150,485 shares during the period. Perceptive Advisors LLC raised its holdings in Neurocrine Biosciences by 70.1% in the 4th quarter. Perceptive Advisors LLC now owns 270,794 shares of the company’s stock worth $35,680,000 after purchasing an additional 111,552 shares in the last quarter. Finally, Van ECK Associates Corp lifted its position in shares of Neurocrine Biosciences by 1,325.5% in the 1st quarter. Van ECK Associates Corp now owns 92,243 shares of the company’s stock worth $12,722,000 after purchasing an additional 85,772 shares during the period. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the transaction, the director now owns 37,491 shares in the company, valued at approximately $5,499,554.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Neurocrine Biosciences news, insider Julie Cooke sold 900 shares of the company’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $150.04, for a total value of $135,036.00. Following the completion of the sale, the insider now owns 18,202 shares in the company, valued at $2,731,028.08. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director William H. Rastetter sold 14,250 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now directly owns 37,491 shares in the company, valued at approximately $5,499,554.79. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,798 shares of company stock valued at $9,274,196. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on NBIX. Guggenheim boosted their price target on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 4th. Robert W. Baird lifted their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. raised their price objective on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Oppenheimer upped their target price on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $162.20.

Neurocrine Biosciences Stock Up 0.1 %

NBIX opened at $115.22 on Tuesday. Neurocrine Biosciences, Inc. has a twelve month low of $103.63 and a twelve month high of $157.98. The firm has a 50 day moving average price of $135.50 and a 200-day moving average price of $137.42. The stock has a market capitalization of $11.60 billion, a price-to-earnings ratio of 31.74 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The firm had revenue of $590.20 million for the quarter, compared to the consensus estimate of $545.98 million. During the same period in the previous year, the company earned $0.95 earnings per share. Neurocrine Biosciences’s quarterly revenue was up 30.4% compared to the same quarter last year. As a group, analysts expect that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.